Isomorphic Labs and MSD Partner on AI-Driven Oncology Drug Discovery
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Isomorphic Labs and MSD announced a research collaboration to discover therapeutic small molecule candidates against an oncology target. Isomorphic Labs will apply its proprietary drug design engine and use select proprietary data sets supplied by MSD to perform *in silico* predictions and deliver molecular designs. MSD will be responsible for the preclinical, clinical, manufacturing, and commercialization of any products resulting from the collaboration.
From finanznachrichten.de
Why it matters
The collaboration combines Isomorphic Labs' AI approach to drug discovery with MSD's proprietary data resources and deep discovery experience. Under the agreement, Isomorphic Labs receives an upfront payment, is eligible for payments based on milestones, and will receive tiered royalties on net sales. MSD will manage the commercialization of any products derived from the partnership.
From finanznachrichten.de
Who's involved
- Isomorphic LabsAI-first drug design and development company applying its engine to the collaboration.
- MSDCompany responsible for preclinical, clinical, manufacturing, and commercialization of derived products.
Keep exploring
The entities involved
-
Isomorphic Labs
British multinational artificial intelligence company
Nothing else this week.
-
MSD
company in Rome, Italy
Nothing else this week.